<DOC>
	<DOCNO>NCT02404480</DOCNO>
	<brief_summary>This Phase 1 , open-label , first-in-human , safety pharmacokinetic study PTC596 patient advance cancer .</brief_summary>
	<brief_title>PTC596 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Patients must histologically cytologically confirm solid malignancy metastatic unresectable , standard curative measure exist , progress least one line standard therapy standard therapy exist Discontinuation therapy ( include investigational drug , radiotherapy , chemotherapy ) treatment cancer ≥4 week ( ≥6 week nitrosoureas , ≥12 week radiotherapy ) initiation study treatment Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 3 month A measure estimate creatinine clearance ( CrCl ) ≥60 mL/min/1.73 m2 Prior bone marrow/hematopoietic stem cell transplantation History solid organ , bone marrow , progenitor cell transplantation History major surgical procedure within 28 day prior start study treatment Evidence ongoing systemic bacterial , fungal , viral infection . Known human immunodeficiency virus ( HIV ) infection acquiredimmunodeficiency syndrome ( AIDS ) relate illness Any follow past 6 month : myocardial infarction , unstable angina , coronary/peripheral artery bypass graft , congestive heart failure ( New York Heart Association Class III IV ) , cerebrovascular accident , transient ischemic attack , arterial thromboembolic event , pulmonary embolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>